Akero Therapeutics, Inc. announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year. The topline week 36 results from the study, evaluating treatment of patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH), will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.4 USD | +2.05% |
|
+7.44% | +0.21% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.21% | 161.81Cr | |
+16.13% | 12TCr | |
+19.65% | 11TCr | |
+21.22% | 2.65TCr | |
-23.84% | 1.94TCr | |
-17.47% | 1.62TCr | |
-45.95% | 1.52TCr | |
-19.28% | 1.54TCr | |
+63.81% | 1.49TCr | |
+1.94% | 1.35TCr |
- Stock Market
- Equities
- AKRO Stock
- News Akero Therapeutics, Inc.
- Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023